Iranian journal of biotechnology · 2026
Kremen2 Promotes Colorectal Cancer Progression by Activating the EGFR/JAK2/STAT3 Signaling Pathway.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Yu, Wang Ziyuan, Ye Zhichao, Zhou Enjie, Wang Yifan
Аннотация
BACKGROUND: Since the COVID-19 outbreak in 2019, nucleic acid testing has been central to epidemic control and clinical decision-making. However, variability in assay kits and extraction steps can affect sensitivity, specificity, and reproducibility. Systematic evaluation of detection reagents and extraction efficiency is essential to ensure reliable clinical results.
OBJECTIVE: This study aimed to evaluate whether three domestic novel coronavirus nucleic acid detection kits based on fluorescence PCR meet clinical requirements for COVID-19 testing.
MATERIALS AND METHODS: The performance of the kits was assessed through coincidence rate, precision, detection limit, specificity, and interference resistance using standard positive, negative, and interference reference samples. Amplification efficiency of three detection reagents was compared with eight positive clinical samples. Additionally, amplification performance was examined under oscillation and non-oscillation conditions before nucleic acid extraction, and with varying input volumes.
RESULTS: The coincidence rates for both N and ORF1ab genes in positive and negative references were 100%. Precision testing showed intra-batch coefficients of variation (CV) ≤2.26%. The lower detection limit of 5.0E+02 copies/mL was consistently detected in all repetitions. No cross-reactivity was observed with Influenza A/B, respiratory syncytial virus, parainfluenza virus, Epstein-Barr virus, or Mycobacterium tuberculosis. Interference testing with hemoglobin, bilirubin, triglyceride, oseltamivir, azithromycin, ceftriaxone, and NaCl demonstrated no impact on detection. Comparative analysis showed significant differences in amplification efficiency among the three reagents for both N and ORF1ab genes (p<0.05), with reagent 2 exhibiting faster reaction cycles and reagent 1 providing greater stability. Significant disparities were also observed between oscillated and unoscillated samples (p<0.05), and across different input volumes (notably between 100 μL vs. 200 μL and 200 μL vs. 300 μL).
CONCLUSIONS: The evaluated kits met clinical performance standards for coincidence rate, precision, detection limit, specificity, and resistance to interference. While amplification efficiencies differed among reagents and experimental conditions, all satisfied clinical diagnostic requirements. These findings underscore the importance of systematic performance verification and optimization of sample handling to ensure reliable nucleic acid detection for COVID-19.
OBJECTIVE: This study aimed to evaluate whether three domestic novel coronavirus nucleic acid detection kits based on fluorescence PCR meet clinical requirements for COVID-19 testing.
MATERIALS AND METHODS: The performance of the kits was assessed through coincidence rate, precision, detection limit, specificity, and interference resistance using standard positive, negative, and interference reference samples. Amplification efficiency of three detection reagents was compared with eight positive clinical samples. Additionally, amplification performance was examined under oscillation and non-oscillation conditions before nucleic acid extraction, and with varying input volumes.
RESULTS: The coincidence rates for both N and ORF1ab genes in positive and negative references were 100%. Precision testing showed intra-batch coefficients of variation (CV) ≤2.26%. The lower detection limit of 5.0E+02 copies/mL was consistently detected in all repetitions. No cross-reactivity was observed with Influenza A/B, respiratory syncytial virus, parainfluenza virus, Epstein-Barr virus, or Mycobacterium tuberculosis. Interference testing with hemoglobin, bilirubin, triglyceride, oseltamivir, azithromycin, ceftriaxone, and NaCl demonstrated no impact on detection. Comparative analysis showed significant differences in amplification efficiency among the three reagents for both N and ORF1ab genes (p<0.05), with reagent 2 exhibiting faster reaction cycles and reagent 1 providing greater stability. Significant disparities were also observed between oscillated and unoscillated samples (p<0.05), and across different input volumes (notably between 100 μL vs. 200 μL and 200 μL vs. 300 μL).
CONCLUSIONS: The evaluated kits met clinical performance standards for coincidence rate, precision, detection limit, specificity, and resistance to interference. While amplification efficiencies differed among reagents and experimental conditions, all satisfied clinical diagnostic requirements. These findings underscore the importance of systematic performance verification and optimization of sample handling to ensure reliable nucleic acid detection for COVID-19.